Event Programme

Please, visit again for updates to the programme.
All dates and times are in Singapore time (‎UTC+8)‎

  • Day 1 Friday 22 October 2021
  • Day 2 Saturday 23 October 2021
  • Virtual Auditorium 1
  • Virtual Auditorium 2
  • Virtual Auditorium 3
08:25 - 08:30Opening of Conference By Gavin Dawe / Tan Chay HoonLocal Organising Committee

Welcome and Opening Ceremony

08:30 - 09:30Plenary Session 1 – “Challenges in the Treatment of Bipolar Disorders: Looking Ahead” By Lakshmi Yatham, University of British ColumbiaProfessor

Bipolar disorder is a complex psychiatric condition with pleomorphic presentations, varied course and high comorbidity. While several options are available for treating mania and preventing mania, many challenges remain in providing optimal outcomes for patients with bipolar disorder. For instance, treatment options continue to be limited for treating acute depressive symptoms in patients with bipolar I and bipolar II disorder and few proven strategies are available for preventing relapse of depressive episodes. Similarly, while cognitive impairment is common and impacts functioning in patients with BD, no proven treatments exist for improving cognition in BD. Comorbidities are common in bipolar disorder, and there is limited data to guide management of such patients. Finally, prevention of mood episodes in patients at high risk for BD remain unexplored. This presentation will review these challenges and suggest some strategies to advance the field.

Chairperson:  Chay Hoon Tan, Singapore

09:30 - 11:00Meet the Experts 1 – “Advances in the Understanding and Management of Treatment Resistance in Schizophrenia: Practical Considerations” By John Kane, Zucker Hillside Hospital, The Donald and Barbara Zucker School of Medicine Professor

Schizophrenia continues to present a major public health problem associated with enormous personal suffering, diminished functioning, family burden and societal costs. Although current treatments (ideally combinations of medication and psychosocial modalities) can substantially improve outcome for many affected individuals, a substantial subgroup qualifies as having “treatment resistant schizophrenia (TRS).” Estimates suggest that 15-20% of patients at their very first episode of psychosis do not derive expected/sufficient benefit from antipsychotic medications. Over time this proportion increase to greater than 30%. In recent decades considerable research has been done evaluating the efficacy of a variety of treatment for these individuals. At the same time there has been insufficient consensus on how to define treatment resistance and many clinical trials employed different criteria for inclusion of subjects. The TRIPP guidelines, published in 2017, were an attempt to provide a consensus of international experts on how to define TRS.

Clozapine remains the only specific medication that has received regulatory approval in many countries for the treatment of TRS. At the same time, however, it remains markedly underutilized. Although there remains some debate regarding clozapine’s unique qualities, a good deal of research supports its role in the management of TRS. Research also suggests that clozapine’s efficacy is greater if it is administered within one to two years after the emergence of TRS.

We still lack good biomarkers to identify those individuals likely to experience TRS and those most likely to benefit from clozapine; however, promising leads have emerged in prospective clinical assessment as well as the use of resting state MRI, PET and EEG perspectives.

Recent research has also suggested that psychotic relapse is associated with poorer response to standard treatment than that observed in prior episodes, suggesting that repeated relapse might also be part of the trajectory towards TRS.

Chairperson:  Jimmy Lee, Singapore

11:00 - 12:30Symposium 2 – “Schizophrenia: from clinical heterogeneity to innovative treatment approaches” By Symposium Speakers - 1. Weihua Yue; 2. Fei Wang; 3. Yamin Zhang; 4. Xueli YuProfessor

Hypermethylation of RUFY1 associated with high risks of schizophrenia and poor treatment responses in Han Chinese
Weihua Yue, China

Frontal-posterior functional imbalance and aberrant function developmental patterns in schizophrenia
Fei Wang, China

The role of white blood cell counts in metabolic changes and clinical symptom improvement after antipsychotics in patients with schizophrenia: evidence from a large Chinese cohort
Yamin Zhang, China

Developing new drugs for schizophrenia: Mechanism study of fingolimod and a novel AMPA receptor positive allosteric modulator LT-102 as therapeutic agents for facilitating cognitive function in schizophrenia model
Xueli Yu, China

Chairperson: Tao Li, China

12:30 - 13:30Poster Viewing By Poster Presenters and JudgesLunch and Posters

Lunch break and poster viewing

13:30 - 15:00Symposium 3 – “REAP Bipolar Disorder and Mood Stabiliser Study: What we found and what we have learned” By Symposium Presenters - 1. Vie Cheong Thong; 2. Isa Multazam Noor; 3. Pornjira Pariwatcharakul; 4. Lin Shih KuProfessor

Polypharmacy in Bipolar disorder: Findings from REAP Bipolar Disorder study
Vie Cheong Thong, Malaysia

Clinical use of mood stabilizers in REAP Study – Focus on clinical symptoms of bipolar disorder
Isa Multazam Noor, Indonesia

Clinical use of mood stabilizers in Asian patients: summary from REAP-BD and MS studies
Pornjira Pariwatcharakul, Thailand

Research on Asian Psychotropic Prescription Patterns on Minor Psychiatric Disorders: Focusing on Generalized Anxiety disorder, Obsessive Compulsive Disorder and Panic Disorder
Lin Shih Ku, Thailand

Chairperson: Lin Shih Ku, Taiwan

15:00 - 16:30Meet the Experts 2 (Otsuka) – “Advances in the understanding and management of treatment resistance in bipolar disorder” By Eduard Vieta, University of BarcelonaProfessor

“Treatment resistance” is a definition that does not belong to the classification system, because it depends on the availability of suitable therapies at a given point in history. However, it has regulatory implications, and it may be useful for clinical practice. Treatment resistance is quite well defined in the field of depression, but not so much in the field of bipolar disorder: hence, concepts such as “treatment resistent mania”, “treatment resistent bipolar depression” and “treatment resistent bipolar disorder” await standardized definitions that may guide clinical practice. This presentation will review this concepts and provide hints for optimal treatment of all those clinical scenarios, with a sight to the future.

Chairperson: Yu Wei Lee, Singapore

Provision of the virtual auditorium venue for this session is made possible by a kind donation from Otsuka Pharmaceutical Co., Ltd to the Pharmacological Society (Singapore).

16:30 - 17:30Plenary Session 2 – “Evidence Based Mental Health in the Real World: Promises, Challenges and Future Directions” By Andrea Cipriani, University of OxfordProfessor

An evidence-based decision about a specific intervention (either pharmacological or not) is not determined only by its demonstrated efficacy and tolerability; it may vary from one patient to another depending on individual clinical circumstances (sex, age, clinical history, etc) and personal preferences. However, ‘evidence’ is not necessarily ‘evident’. Evidence is anything presented in support of an assertion. This support may be strong or weak, but it is the closest that we can get to the truth itself and the only objective starting point we can use for our clinical reasoning. We need all good quality, available data to justify our rational choice; otherwise patients will be treated according to mere opinion. This is the reason why I strongly disagree with opponents of Evidence Based Mental Health who say that it is the wrong paradigm to answer our routine clinical questions. On the contrary, given the inevitability of biases and inaccuracies in the scientific literature, we have a simple choice: we can either make the best use of the available evidence or dismiss and ignore it. Clinicians (and patients and carers) should favour the former approach and reject nihilism. Valid conclusions can be drawn from a critical and cautious use of the best available, if flawed, evidence. Also ‘the best available evidence’ implies the continuous update and progress of scientific knowledge, doubting, testing and retesting previous findings. Scientific knowledge in medicine can develop and increase only if there are researchers, clinicians, patients and public who strive to see things from a different perspective, always pursuing the truth (which almost always means avoiding easy answers). Evidence Based Mental Health should be seen as a tool to engage new generations of psychiatrists and psychologists to develop and implement the evidence-based approach into daily clinical practice.

Chairperson: Roger Ho, Singapore

09:30 - 11:00Symposium 1 – “New treatment modalities in neuropsychiatric disorders” By Symposium Speakers - 1. Dennis Velakoulis; 2. Mark Walterfang; 3. Simon DucharmeProfessor

Novels treatments in Huntington’s disease and frontotemporal dementia – an Australian perspective
Dennis Velakoulis, Australia

Neuropsychiatric Aspects of Niemann Pick Type C Disease in Adults
Mark Walterfang, Australia

Advances in pharmacological treatments of Alzheimer’s Dementia and Fronto-Temporal Dementia
Simon Ducharme, Canada

Chairperson:  Cyrus Ho, Singapore

11:00 - 12:30Special Session 1 (Sumitomo) – “Tx of bipolar depression: Lows are not forever” By Speakers - 1. Ya Mei Bai; 2. Leslie CitromeProfessor

Asian Perspective on Challenges in Managing Bipolar I Disorder (Bipolar Depression)
Ya Mei Bai, Taiwan

Navigating the Lows: Current Evidences on Pharmacological Treatment for Bipolar I Disorder (Bipolar Depression)
Leslie Citrome, USA

Chairpersons:
Ya Mei Bai, Taiwan
Leslie Citrome, USA

Provision of the virtual auditorium venue for this session is made possible by a kind donation from Sumitomo Pharmaceuticals Asia Pacific to the Pharmacological Society (Singapore).

12:30 - 13:30Special Session 2 (Servier) – “Overcoming emotional blunting in the treatment of depression” By David CastleProfessor

Chairperson:  Roger Ho, Singapore

This session is made possible by kind support from Servier.

13:30 - 15:00Symposium 4 – How do microglia contribute to psychiatric disorders? – Immunological crosstalk between mind and body. By Symposium Speakers - 1. Tomoyuki Furuyashiki; 2. Shin-ichi Kano; 3. Laura Maggi; 4. Gen Shinozaki; 5. Takahiro A. KatoProfessor

Multiple modes of stress-induced inflammation in the brain and periphery
Tomoyuki Furuyashiki, Japan

Thalamic microglial activation and cognitive impairment
Shin-ichi Kano, USA

Interaction between microglia and neurons: role in stress sensitivity and depression treatment
Laura Maggi, Italy

Epigenetics, neuroinflammation and aging: genome-wide DNA methylation of delirium
Gen Shinozaki, USA

Human blood-induced microglia-like (iMG) cells as a reverse translational research tool to clarify mind-brain-body interactions
Takahiro A. Kato, Japan

Chairpersons: 
Takahiro Kato, Japan
Tomoyuki Furuyashiki, Japan
Cyrus Ho, Singapore

15:00 - 16:30Oral Presentations 1 – Pain/Basic Science By Oral Speakers - 1. Yu Miyahara; 2. Seii Ohka; 3. Daisuke Nishizawa; 4. Ryo Sawagashira Prof / A/Prof / Dr

Differential roles of 5-HT3 and 5-HT7 receptors in acute pruriceptive processing in mice
Yu Miyahara, Japan

A gene genetically associated with herpes zoster or post-herpetic neuralgia has impacts on varicella-zoster virus-mediated fusogenic activity
Seii Ohka, Japan

Association between postoperative analgesia after major abdominal surgery and a single nucleotide polymorphism rs12496846 in the C3orf20 gene region, identified to be associated with postoperative analgesia after mandibular sagittal split ramus osteotomy
Daisuke Nishizawa, Japan

The oculomotor foraging task: a novel behavioral paradigm to evaluate multiple components of working memory
Ryo Sawagashira, Japan

Chairperson: Gavin Dawe

09:30 - 11:00Symposium 10 – “The Effects of Covid-19 pandemic on the treatment of mental disorders” By Symposium Speakers - 1. Li Yi; 2. Guangyin Zhang; 3. Andi J Tanra; 4. Tji Tjian Chee; 5. Buvanaswari P Prof / A/Prof / Dr

The impact of COVID-19 on the treatment model of mental disorders 
Li Yi, China

Mental health outcomes among patients exposed to COVID-19 : Experience from Fangcang shelter hospital
Guangyin Zhang, China

Lessons Learned from Covid-19 Pandemic: Indonesia’s Perspective
Andi J Tanra, Indonesia

Health Care Worker Wellness During Covid-19: The New Normal in Singapore
Tji Tijan Chee, Singapore

The Hidden Pandemic: Rising to meet Mental Health Challenges during Covid-19
Buvanaswari P, Singapore

Chairperson:  Li Yi, China

11:00 - 12:30Symposium 11 – “Update on Treatment of Schizophrenia using Atypical Antipsychotics” By Symposium Speakers - 1. Ahmad Hatim B Sulaiman; 2. Kristian Liaury; 3. Norio Yasui-Furukori; 4. Andi Tanra Professor

Optimizing Treatment for Patients with Schizophrenia
Ahmad Hatim B Sulaiman, Malaysia

Effect of Adjuvant Vitamin C on Brain-Derived Neurotrophic Factor (BDNF) Levels and Improvement of Negative Symptoms in Schizophrenic Patients
Kristian Liaury, Indonesia

Recent Trend in Neuropsychopharmacology in Japan
Norio Yasui-Furukori, Japan

Profiles of antipsychotic use among schizophrenia patients in Indonesia: Results from the REAP Study
Andi Tanra, Indonesia

Chairperson: Andi Tanra, Indonesia

15:00 - 16:30Symposium 12 – “Guideline for Pharmacological Therapy of Schizophrenia by JSNP” By Symposium Speakers - 1. Hiroyuki Uchida; 2. Kenji Sakuma; 3. Hikaru Hori; 4. Hiroyoshi Takeuchi; 5. Ryota Hashimoto Professor

Introduction of the Guideline for Pharmacological Therapy of Schizophrenia
Hiroyuki Uchida, Japan  

Implementing Evidence-Based Practices for People with Schizophrenia in Japan
Kenji Sakuma, Japan  

Pharmacological Treatment of Relapse/Recurrence in Patients with Schizophrenia
Hikaru Hori, Japan  

Maintenance Treatment of Schizophrenia
Hiroyoshi Takeuchi, Japan  

Treatment Resistance Schizophrenia
Ryota Hashimoto, Japan     

Chairperson: Ryoto Hashimoto

This symposium is presented by the Japanese Society of Neuropsychopharmacology (JSNP)

  • Virtual Auditorium 1
  • Virtual Auditorium 2
  • Virtual Auditorium 3
08:30 - 09:30Plenary Session 3 – “Artificial Intelligence in the Pharmacological Treatment of Psychiatric Conditions” By Roger S. McIntyre, University of TorontoProfessor

Depression is a complex and often chronic illness. Improving health outcomes in depression begins with improving characterization of the illness in those affected. Ecological momentary assessment (EMA) provides opportunity for passive and ambient collection of data that EMA devices suggest can determine whether a patient is depressed or not. Notwithstanding the availability of multiple app-based technologies, most require patient direct entry of some sort which the literature indicates will be insufficient from the point of view of adherence. Passive collection of data does not require any direct entry by the end user and has the ability to inform not only the person living with the illness but also their healthcare providers whether their illness is active and requires treatment. It may also be able to determine whether persons at greater risk of suicide which is being looked at with future research. This presentation will discuss the role of technology in the detection, treatment and management of mental disorders with a focus on depression and the role of artificial intelligence (AI) in treatment discovery and clinical care.

Chairperson: Kang Sim, Singapore

09:30 - 11:00Symposium 5 – “Immune markers in psychiatric disorders” By Symposium Speakers - 1. Roger Ho; 2. Kristian Liaury; 3. Po See Chen; 4. Ya Mei BaiProfessor

Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression
Roger Ho, Singapore

Therapeutic strategy in schizophrenia by targeting neuroinflammation
Kristian Liaury, Indonesia

Immune markers in psychiatric disorders: leptin-modulated corticostriatal circuitry in bipolar I and bipolar II disorders
Po See Chen, Taiwan

Inflammatory markers and Mood Disorders: Proinflammatory Cytokine Dysregulation, Cognitive Dysfunction, and Reduced Gray Matter Volumes among Patients with Bipolar Disorder and Major Depressive Disorder
Ya Mei Bai, Taiwan

Chairperson: Ya Mei Bai, Taiwan

 

11:00 - 12:30Meet the Experts 3 – “Building evidence for sequenced depression treatment” By Toshi A. Furukawa, Kyoto University Graduate School of Medicine / School of Public HealthProfessor

In 2009 we published one of the earlier network meta-analyses (NMA) of 12 new generation antidepressants in the acute phase treatment of depression 1. In 2018 we expanded and updated this NMA by including five more new generation antidepressants and four old antidepressants (522 trials, 116 477 participants) 2. The major difficulty in these endeavors was to identify unpublished trials, as publication bias has unfortunately been the pervasive practice not only in psychopharmacology but in biology and science at large 3. Through extensive collaboration with some industry and regulatory agencies, we were able to identify 86 unpublished trials and find unpublished information for 188 additional trials. The results challenged the old clinical wisdom that there are no major differences in efficacy among antidepressants.

Examination of the response rates on placebo among the included studies in the past four decades cast serious doubts on the decade-long superstition that the placebo response rate was increasing over the years in antidepressant trials. There was a structural break in 1991, and since then, the average placebo response rates in antidepressant trials have remained constant in the range between 35% and 40% 4.

The comprehensive dataset has also enabled us to conduct the dose-response meta-analysis of SSRIs, venlafaxine and mirtazapine based on a sizable number of fixed-dose trials. The results suggested a dose-response up to doses between 20 mg and 40 mg of fluoxetine equivalents, and a flat to decreasing trend through the higher licensed doses. Dropouts due to adverse effects increased steeply through the examined range. Taken together, for these commonly used second-generation antidepressants, the lower range of the licensed dose achieved the optimal balance between efficacy, tolerability, and acceptability 5. Using the flexible adjustment in accordance with the patient’s response did not confer any benefit over prescribing at the minimum licensed dose 6.

A large pragmatic trial comparing the minimum vs maximum dose of sertraline as the first step treatment for hitherto untreated episodes of major depression and comparing second-line strategies of continuation vs switching to mirtazapine vs augmentation with mirtazapine if the patients do not remit by week 3 confirmed the above findings 7.

The exiting psychopharmacology guidelines should be rewritten: (1) Start with one of the more efficacious and acceptable antidepressants, (2) Aim at the minimum licensed dose; do not titrate to the maximum, (3) Switch or augment if the patients do not show early response.

1.         Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373:746-758.

2.         Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366.

3.         Ioannidis JP. Acknowledging and Overcoming Nonreproducibility in Basic and Preclinical Research. JAMA. 2017.

4.         Furukawa TA, Cipriani A, Atkinson LZ, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016;3(11):1059-1066.

5.         Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601-609.

6.         Furukawa TA, Salanti G, Cowen PJ, Leucht S, Cipriani A. No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review. Acta Psychiatr Scand. 2020;141(5):401-409.

7.         Kato T, Furukawa TA, Mantani A, et al. Optimising first- and second-line treatment strategies for untreated major depressive disorder – the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Med. 2018;16(1):103.

Chairperson: Johnson Fam

12:30 - 13:30Poster Viewing By Poster Presenters and JudgesLunch and Posters

Lunch break and poster viewing

13:30 - 15:00Symposium 7 – “Meta-Analyses of Treatments in Psychiatric Disorders: Practical pointers for clinicians” By Symposium Speakers - 1. Han Qi; 2. Yuan Yuan Wang; 3. Wenwang Rao; 4. Yikang ZhuProfessor

Efficacy and safety of adjunctive aripiprazole, metformin and paeoniae-glycyrrhiza decoction for antipsychotic-induced hyperprolactinemia: a network meta-analysis of randomized controlled trials
Han Qi, China

Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer’s disease
Yuan Yuan Wang, UK

Efficacy and safety of traditional Chinese herbal medicine for antipsychotic-related constipation: a systematic review and meta-analysis of randomized controlled trials
Wenwang Rao, China

Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis
Yikang Zhu, China

Chairpersons:
Yu Tao Xiang, China
Sim Kang, Singapore

15:00 - 16:30Symposium 8 – “Schizophrenia and depression research: state-of-the-art knowledge and the future” By Symposium Speakers - 1. Xin-Min Li; 2. Yanbo Zhang; 3. Yuan-Hwa Chou; 4. Lin Shih Ku Professor

Future of Psychiatry: Role of Technology
Xin-Min Li, Canada

Advances in psychotherapy/pharmacotherapy enhanced neuromodulation in treating major depressive disorder
Yanbo Zhang, Canada

TBC
Yuan-Hwa Chou, Taiwan

Pipeline Medications for Schizophrenia
Lin Shih Ku

Chairperson: Lin Shih Ku, Taiwan

16:30 - 16:40Closing Ceremony By Roger Ho Chun Man / Sim Kang / Ho Su Hui, CyrusLocal Organizing Committee

Closing Remarks and Announcement of Best Oral Presentation and Poster Awards

09:30 - 11:00Symposium 6 – “Neuropsychopharmacology and mental health in COVID-19 pandemic” By Symposium Speakers - 1. Shinya Kasai; 2. Roger McIntyre; 3. Roger Ho; 4. Minh-Anh LeProfessor

Genetic association between COVID-19 and substance use disorders
Shinya Kasai, Japan

Using Psychotropic Drugs to Treat Long-Covid Syndrome
Roger McIntyre, Canada

A chain mediation model on COVID-19 symptoms and mental health outcomes in America, Asia and Europe
Roger Ho, Singapore

Feasibility and Effectiveness of Art therapies for improving health and well-being of children during COVID-19: A global synthesis
Minh-Anh Le, USA

Chairperson: Shinya Kasai, Japan

11:00 - 12:30Oral Presentations 2 – Clinical Psychiatry By Oral Speakers - 1. Taisuke Yatomi; 2. Kotaro Hatta; 3. Wang Yuxi; 4. Kuan-Pin SuProf / A/Prof / Dr

Prescription of unfavorable combinations of drugs for mood disorders and physical conditions: a cross-sectional national database survey
Taisuke Yatomi, Japan

Real-world effectiveness of antipsychotic treatments in a psychiatric emergency cohort of 1011 patients with schizophrenia
Kotaro Hatta, Japan

High Dose Mood Stabiliser use and Clinical Correlates Amongst Patients with Bipolar Disorder in Asia: Research on Asian Psychotropic Prescription Patterns
Wang Yuxi, Singapore

Omega-3 fatty acids in depression: The clinical and psychoneuroimmunolgical implications
Kuan-Pin Su, China

Chairperson: Tji Tjian, Singapore

12:30 - 13:30AsCNP Lundbeck Science Award

Professor Tadafumi Kato

Head of Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine. Tokyo, Japan

Professor Zhong Chen

President of Zhejiang Chinese Medical University, and also the Prof of School of Medicine, Zhejiang University,  Hangzhou, Zhejiang Province, China  

Chairperson: Chay Hoon Tan

13:30 - 15:00Special Session 4 (Lundbeck) – “Evolution of the pharmacological treatment for MDD-monotherapy or combination therapy?”   By Speakers - 1. Andrea Fagiolini; 2 .Philip GorwoodProfessor

Andrea Fagiolini, Italy

Philip Gorwood, France

Chairpersons:  Chay Hoon Tan, Singapore

This session is made possible by kind support from Lundbeck.

15:00 - 16:30Symposium 9 – “Advances in computational neuropsychopharmacology – progress and challenge” By Symposium Speakers - 1. Yina Ma; 2. Rongjun Yu; 3. Jonathan Kanen; 4. Benjamin BeckerProfessor

Oxytocin begets large-scale cooperation: A biobehavioral mechanism for the dynamic spread of cooperation in human social networks
Yina Ma, China

Brain networks under acute stress
Rongjun Yu, Hong Kong

Examining flexible decision-making in compulsive disorders and after pharmacological challenges using computational modelling
Jonathan Kanen, UK

Precision pharmaco-imaging: development and application of a neuroimaging-based fear signature
Benjamin Becker, China

Chairperson:  Benjamin Becker

08:30 - 11:15Special Session 3 (Hyphens) – Child and Adolescent Psychiatry By Speakers - 1. Timothy Wilens; 2. Joshi Gagan Professor

Pharmacological Strategies in Complex ADHD
Timothy E Wilens, USA

Advanced psychopharmacologic treatment for Child and Adolescent with Autism Spectrum Disorder
Joshi Gagan, USA

Chairperson: John Wong, Singapore

This session is made possible by kind support from Hyphens.

Submit an Abstract Now

Abstract submission deadline: 5 pm July 16, 2021 (Singapore time)
ABSTRACT SUBMISSIONS NOW CLOSED